Tivozanib Hydrochloride Patent Expiration

1. Fotivda patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7166722 AVEO PHARMS N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
Nov, 2024

(4 months from now)

US6821987 AVEO PHARMS Quinoline derivatives and quinazoline derivatives having azolyl group
Apr, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS Use of tivozanib to treat subjects with refractory cancer
Nov, 2039

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2026

NCE-1 date: 10 March, 2025

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...

Dosage: CAPSULE

More Information on Dosage

FOTIVDA family patents

Family Patents